{"id":8494,"date":"2026-08-21T10:26:30","date_gmt":"2026-08-21T08:26:30","guid":{"rendered":"https:\/\/mumak.me\/?p=8494"},"modified":"2026-08-21T12:06:46","modified_gmt":"2026-08-21T10:06:46","slug":"valuation-analysis-moderna","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/research-insights\/valuation-analysis\/valuation-analysis-moderna\/","title":{"rendered":"Valuation Analysis: Moderna"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\"\"\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t

Moderna, Inc.<\/h4>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tAnalysis result: 4 out of 5 MUMAKS\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Moderna is a biotechnology company whose business model is based on its own messenger RNA (mRNA) platform<\/strong>. After gaining global recognition for its COVID-19 vaccine, Moderna is working to expand its business into other areas such as respiratory diseases, oncology, infectious diseases, and rare diseases<\/strong>.<\/p>

This transformation has gained importance as revenues from COVID-19 vaccines have significantly declined from their peak during the pandemic.<\/p>

Two developments in August 2026 significantly improved the company’s strategic position. On August 5, 2026<\/strong>, the FDA granted approval for mFLUSIVA<\/strong>, Moderna’s seasonal influenza vaccine for adults aged 50 and older. Even more significant was the announcement on August 19, 2026<\/strong>: Moderna and Merck released positive topline results from the Phase 3 study of Intismeran Autogene in melanoma<\/strong>.<\/p>

Assessment<\/h2>

This analysis assesses Moderna according to the MUMAK UMBRELLA Strategy.<\/span><\/p>

The valuation is carried out across five decision phases: Geopolitics<\/strong>, Industry<\/strong>, Fundamentals<\/strong>, Market Sentiment<\/strong>, and Technical Analysis.<\/strong><\/span><\/p>

The goal is not to predict the future exactly. The goal is orientation. We classify facts, show the interdependencies, and structure a transparent decision logic.<\/span> <\/span><\/p>

We explain \u2013 you decide.<\/span><\/b> <\/span><\/p>

Geopolitics<\/h3>

Classification <\/strong><\/h4>

Moderna operates in an environment where biotechnology, vaccine production, and pandemic preparedness<\/strong> are increasingly of strategic importance to governments.<\/p>

The COVID-19 pandemic demonstrated the importance of rapid vaccine development, proprietary production capacities, and secure pharmaceutical supply chains. Governments in the US, Europe, and other regions continue to work on improving their preparedness for future health crises.<\/p>

Moderna benefits from this development through its mRNA technology platform<\/strong>, which allows vaccines and therapeutics to be developed comparatively quickly and adapted to new pathogens or therapeutic targets.<\/p>

International relations with government agencies also increase the company’s strategic relevance. In 2026, Moderna continued deliveries under its long-term partnership with the UK government. At the same time, a joint procurement agreement with the European Commission for up to 24 million doses of mRESVIA<\/strong> for six European countries was concluded.<\/p>

At the same time, the political environment for mRNA vaccines in the US has become more challenging. Changes in government policy and reduced government support for certain mRNA vaccine development programs increase uncertainty, particularly in the area of respiratory diseases.<\/p>

However, the increasing expansion into oncology and personalized medicine<\/strong> reduces Moderna’s dependence on government vaccine programs and extends the strategic importance of the technology beyond infectious diseases.<\/p>

Opportunities<\/h5>